Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.

MLA

Lanzillo, Roberta, et al. “Immunometabolic Profiling of Patients with Multiple Sclerosis Identifies New Biomarkers to Predict Disease Activity during Treatment with Interferon Beta-1a.” Clinical Immunology (Orlando, Fla.), vol. 183, Oct. 2017, pp. 249–53. EBSCOhost, https://doi.org/10.1016/j.clim.2017.08.011.

APA

Lanzillo, R., Carbone, F., Quarantelli, M., Bruzzese, D., Carotenuto, A., De Rosa, V., Colamatteo, A., Micillo, T., De Luca Picione, C., Saccà, F., De Rosa, A., Moccia, M., Brescia Morra, V., & Matarese, G. (2017). Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. Clinical Immunology (Orlando, Fla.), 183, 249–253. https://doi.org/10.1016/j.clim.2017.08.011

Chicago

Lanzillo, Roberta, Fortunata Carbone, Mario Quarantelli, Dario Bruzzese, Antonio Carotenuto, Veronica De Rosa, Alessandra Colamatteo, et al. 2017. “Immunometabolic Profiling of Patients with Multiple Sclerosis Identifies New Biomarkers to Predict Disease Activity during Treatment with Interferon Beta-1a.” Clinical Immunology (Orlando, Fla.) 183 (October): 249–53. doi:10.1016/j.clim.2017.08.011.